Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Egypt J Immunol ; 19(1): 11-8, 2012.
Article in English | MEDLINE | ID: mdl-23888547

ABSTRACT

Infection with Helicobacter pylori has been associated with Iron deficiency anemia (IDA). We assessed the effect of eradication of H. pylori infection on response to oral iron treatment. Twenty patients with IDA of no obvious cause, unresponsive to oral iron therapy with positive gastric biopsy for H. pyJoril infection received sequential eradication therapy for 10 days followed by oral iron therapy. Treated patients were followed up at 6 weeks and 12 weeks post eradication to assess dynamic changes in hemoglobin, serum ferritin and transferrin saturation. While 65% of anemic H. pylori infected cases had pangpstritis, 35% had antral gastritis. In the antrum severe and moderate gastritis were found in 40% and 45% of cases, respectively. Hemoglobin and serum ferritin level correlated inversely with grade of gastritis (P <0.001). Improvement in hematological parameters and serum iron profile was observed 6 weeks and 12 weeks post successful H. eradication oral iron therapy. In conclusion, eradication of H. pylori infection enhances the response to oral iron supplementation in patients with refractory IDA. Screening and eradication of H. pylori should be a standard procedure for patients with IDA.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Anti-Bacterial Agents/therapeutic use , Helicobacter Infections/drug therapy , Iron/administration & dosage , Administration, Oral , Adult , Anemia, Iron-Deficiency/complications , Drug Therapy, Combination , Female , Helicobacter Infections/complications , Helicobacter Infections/pathology , Helicobacter pylori , Humans , Male , Middle Aged , Proton Pump Inhibitors/therapeutic use , Stomach/microbiology , Stomach/pathology
2.
World J Gastroenterol ; 16(33): 4145-51, 2010 Sep 07.
Article in English | MEDLINE | ID: mdl-20806430

ABSTRACT

AIM: To demonstrate the therapeutic effect of probiotics in patients with ulcerative colitis (UC), and their effect on inflammatory mediators and nuclear factor (NF)-kappaB activation in these patients. METHODS: Thirty patients with mild to moderate UC were randomly classified into two groups: sulfasalazine group, who received sulfasalazine 2400 mg/d; and probiotic group, who received sulfasalazine 2400 mg/d with probiotic. The patients were investigated before and after 8 wk of treatment with probiotic (Lactobacillus delbruekii and Lactobacillus fermentum). Colonic activity of myeloperoxidase (MPO) was assayed with UV spectrophotometry, the colonic content of interleukin (IL)-6 was determined by enzyme-linked immunosorbent assay (ELISA), fecal calprotectin was determined by ELISA, and expression of NF-kappaB p65 and tumor necrosis factor (TNF)-alpha proteins in colonic tissue was identified by immunohistochemistry and reverse transcription polymerase chain reaction, respectively. RESULTS: At the start of the study, colonic mucosal injury and inflammation were demonstrated in UC patients by hematoxylin and eosin staining, and an increase in colonic MPO activity, fecal calprotectin, and expression of colonic TNF-alpha and NF-kappaB p65 proteins. The use of probiotic for 8 wk significantly ameliorated the inflammation by decreasing the colonic concentration of IL-6, expression of TNF-alpha and NF-kappaB p65, leukocyte recruitment, as demonstrated by a decrease in colonic MPO activity, and the level of fecal calprotectin compared to sulfasalazine group and the control group (P < 0.05). CONCLUSION: Oral supplementation with probiotics could be helpful in maintaining remission and preventing relapse of UC.


Subject(s)
Colitis, Ulcerative/metabolism , Interleukin-6/metabolism , NF-kappa B/metabolism , Probiotics/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Colitis, Ulcerative/drug therapy , Feces , Female , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Lactobacillus delbrueckii/physiology , Limosilactobacillus fermentum/physiology , Leukocyte L1 Antigen Complex/metabolism , Male , Middle Aged , Peroxidase/metabolism , Probiotics/therapeutic use , Sulfasalazine/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...